Friday, July 10, 2026

pharma · Advanced Cancer · Non-small Cell Lung Cancer · RCUS

Arcus Biosciences

Arcus Biosciences is a pharma organization headquartered in Hayward, USA. It trades on NYSE under ticker RCUS. Primary therapeutic focus areas include Advanced Cancer, Non-small Cell Lung Cancer, Metastatic Clear Cell Re

3928 Point Eden Way, Hayward, California 94545, US HQ
2015 Founded
655 Employees
Public company Type
RCUS · NYSE Ticker
Company details
Status
Public
HQ
3928 Point Eden Way, Hayward, California 94545, US
Founded
2015
Employees
655
Programs
53
Drugs
25
Patents
30
Clinical program

ARC-10

Phase 3 · small molecule · Squamous Non-small cell Lung Cancer, Non-Small Cell Lung Cancer, Non squamous Non Small Cell Lung Cancer, Lung Cancer

ARC-10 for Squamous Non-small cell Lung Cancer, Non-Small Cell Lung Cancer, Non squamous Non Small Cell Lung Cancer, Lung Cancer is a Phase 3 program (small_molecule) at Arcus Biosciences with 1 ClinicalTrials.gov record(s).

← All Arcus Biosciences projects Phase 3 small molecule active

Internal code ARC-10

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Arcus Biosciences
Phase
Phase 3
Modality
small_molecule
Indication
Squamous Non-small cell Lung Cancer, Non-Small Cell Lung Cancer, Non squamous Non Small Cell Lung Cancer, Lung Cancer
Status
active
Trials
1